BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
US Department of Justice
Johnson and Johnson
Julphar
AstraZeneca
UBS
Cantor Fitzgerald
Federal Trade Commission
Express Scripts
Merck

Generated: January 18, 2018

DrugPatentWatch Database Preview

Valeant Intl Company Profile

« Back to Dashboard

Summary for Valeant Intl
International Patents:39
US Patents:4
Tradenames:11
Ingredients:7
NDAs:13

Drugs and US Patents for Valeant Intl

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Intl ATIVAN lorazepam TABLET;ORAL 017794-002 Approved Prior to Jan 1, 1982 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Intl CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-005 Feb 6, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Valeant Intl CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-003 Feb 6, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Valeant Intl CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-004 Feb 6, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Valeant Intl RETIN-A-MICRO tretinoin GEL;TOPICAL 020475-004 Oct 23, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Intl CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-001 Feb 6, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Valeant Intl RETIN-A-MICRO tretinoin GEL;TOPICAL 020475-003 Jan 28, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Valeant Intl CARDIZEM CD diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020062-003 Dec 27, 1991 AB3 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Intl RETIN-A tretinoin SWAB;TOPICAL 016921-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Intl CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-001 Feb 6, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Valeant Intl

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Intl VASERETIC enalapril maleate; hydrochlorothiazide TABLET;ORAL 019221-003 Jul 12, 1995 ➤ Subscribe ➤ Subscribe
Valeant Intl RETIN-A MICRO tretinoin GEL;TOPICAL 020475-001 Feb 7, 1997 ➤ Subscribe ➤ Subscribe
Valeant Intl CARDIZEM CD diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020062-001 Aug 10, 1992 ➤ Subscribe ➤ Subscribe
Valeant Intl CARDIZEM CD diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020062-002 Dec 27, 1991 ➤ Subscribe ➤ Subscribe
Valeant Intl CARDIZEM CD diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020062-004 Dec 27, 1991 ➤ Subscribe ➤ Subscribe
Valeant Intl CARDIZEM CD diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020062-001 Aug 10, 1992 ➤ Subscribe ➤ Subscribe
Valeant Intl CARDIZEM CD diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020062-004 Dec 27, 1991 ➤ Subscribe ➤ Subscribe
Valeant Intl CARDIZEM CD diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020062-004 Dec 27, 1991 ➤ Subscribe ➤ Subscribe
Valeant Intl CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-004 Feb 6, 2003 ➤ Subscribe ➤ Subscribe
Valeant Intl CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-006 Feb 6, 2003 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for VALEANT INTL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Gel 0.04% ➤ Subscribe 12/20/2010
➤ Subscribe Gel 0.1% ➤ Subscribe 7/8/2010
➤ Subscribe Extended-release Tablets 120 mg, 180 mg, 240 mg, 300 mg and 360 mg ➤ Subscribe 8/30/2005
➤ Subscribe Extended-release Tablets 420 mg ➤ Subscribe 4/25/2005
➤ Subscribe Extended-release Tablets 150 mg and 300 mg ➤ Subscribe 9/21/2004

Non-Orange Book US Patents for Valeant Intl

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,145,675 Two step method for preparation of controlled release formulations ➤ Subscribe
5,879,716 Methods and compositions for topical delivery of benzoyl peroxide ➤ Subscribe
6,143,327 Delayed release coated tablet of bupropion hydrochloride ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Valeant Intl Drugs

Supplementary Protection Certificates for Valeant Intl Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2001 Austria ➤ Subscribe PRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011
1304992/01 Switzerland ➤ Subscribe PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
2013025,C1304992 Lithuania ➤ Subscribe PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
C/GB05/029 United Kingdom ➤ Subscribe PRODUCT NAME: MESOTRIONE (2-(4-METHYLSULPHONYL-2-NITROBENZOYL)-1,3CYCLOHEXANEDIONE); REGISTERED: AU 2726 20001016; UK 0309 OF 2005 20050218
13/044 Ireland ➤ Subscribe PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
00043 Netherlands ➤ Subscribe PRODUCT NAME: ALITRETINOIN; NAT. REGISTRATION NO/DATE: EU/1/00/149/001 20001011; FIRST REGISTRATION: EU/1/00/149/001 20001011
C0042 Belgium ➤ Subscribe PRODUCT NAME: 2-(2-BENZOYL-SUBSTITUE)-1,3-CYCLOHEXANE-DIONES; REGISTRATION NO/DATE: 8452/B 19930121
00097 Netherlands ➤ Subscribe PRODUCT NAME: BOSENTAN, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN HYDRAAT OF IN DE VORM VAN EEN ESTER VAN DE HYDROXYLGROEP VAN DE 2-HYDROXYETHOXY REST MET EEN ZUUR MET DE FORMULE R5-OH, WAARIN R5 EEN C1-7-ALKANOYL, BENZOYL, OF HETEROCYCLYCARBONYL VOORSTELT; NATL. REGISTRATION NO/DATE: U/1/02/220/001 - 005 20020515; FIRST REGISTRATION: CH IKS 58841 01 - 02 20020228
172 Luxembourg ➤ Subscribe PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
2008000041 Germany ➤ Subscribe PRODUCT NAME: ADAPALEN IN KOMBINATION MIT BENZOYLPEROXID; NAT. REGISTRATION NO/DATE: 67913.00.00 20080229; FIRST REGISTRATION: DAENEMARK 40440 20071218
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Fish and Richardson
Teva
Harvard Business School
Chubb
UBS
Citi
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot